Hyderabad: Dr Reddy’s Laboratories, the Indian partner of Russian Direct Investment Fund (RDIF), has not only sought approval from the Indian drug regulator for use of the single dose Russian vaccine, Sputnik Light, as a booster to the two-dose Sputnik V, but has also submitted a proposal for conducting trials of Sputnik Light as a booster to other vaccines.
The company is also working on bringing to India the two-dose vaccine for adolescents, Sputnik-M that has been approved by the Russian regulator for use in children in the 12-18 years age group.
“The same data has been made available to us here. We are in the process of reviewing and translating the data and we will be having a conversation with DCGI within the next few months,” Deepak Sapra, CEO, API, Dr Reddy’s Labs said. Pointing out that the company will have to conduct a clinical trial on Indian population for use of Sputnik-M on adolescents in India, he said that would depend on guidanace that regulator will provide to the company.
